Antipsychotic-induced movement disorders - Forgotten but not gone

Acta Psychiatrica Scandinavica

Volumn 117, Issue 6, 2008, Pages 401-402

  Weiden, Peter J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DOPAMINE; NEUROLEPTIC AGENT; PERPHENAZINE;

AKATHISIA; BASAL GANGLION; CLINICAL PRACTICE; DRUG WITHDRAWAL; EDITORIAL; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE; HUMAN; MEDICAL RESEARCH; MORBIDITY; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; PARKINSON DISEASE; PARKINSONISM; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT PLANNING;

AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BRAIN; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DYSKINESIA, DRUG-INDUCED; HUMANS; PARKINSON DISEASE, SECONDARY; RISK FACTORS; SCHIZOPHRENIA;

EID: 43549121453     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2008.01206.x     Document Type: Editorial

References (6)

1. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007 13 : 13 24.
2. Sundram S, Lambert T, Pisculic D. Acculturation is associated with the prevalence of tardive dyskinesia and akathisia in community treated patients with schizophrenia. Acta Psychiatr Scand 2008 117 : 474 478.
3. Lieberman J, Stroup S, Mcevoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 353 : 1209 1223.
4. Weiden PJ. Discontinuation and switching antipsychotic medication: lessons from the CATIE schizophrenia trial. J Clin Psychiatry 2007 68 (Suppl 1 12 19.
5. Weiden PJ, Mann JJ, Haas GL, Mattson M, Frances A. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry 1987 144 : 1148 1153.
6. Dixon L, Weiden PJ, Frances A, Rapkin B. Management of neuroleptic-induced movement disorders: effects of physician training. Am J Psychiatry 1989 146 : 104 105.